TY - JOUR
T1 - Periodontal disease in a patient receiving Bevacizumab
T2 - a case report
AU - Gujral, Dorothy M
AU - Bhattacharyya, Sanjeev
AU - Hargreaves, Peter
AU - Middleton, Gary W
PY - 2008
Y1 - 2008
N2 - Bevacizumab is a monoclonal antibody that inhibits the action of vascular endothelial growth factor (VEGF) thereby acting as an angiogenesis inhibitor. As a result, supply of oxygen and nutrients to tissues is impaired and tumour cell growth is reduced. Reported side effects due to bevacizumab are hypertension and increased risk of bleeding. Bowel perforation has also been reported. Periodontal disease in patients on bevacizumab therapy has not been reported before.
AB - Bevacizumab is a monoclonal antibody that inhibits the action of vascular endothelial growth factor (VEGF) thereby acting as an angiogenesis inhibitor. As a result, supply of oxygen and nutrients to tissues is impaired and tumour cell growth is reduced. Reported side effects due to bevacizumab are hypertension and increased risk of bleeding. Bowel perforation has also been reported. Periodontal disease in patients on bevacizumab therapy has not been reported before.
U2 - 10.1186/1752-1947-2-47
DO - 10.1186/1752-1947-2-47
M3 - Article
C2 - 18271967
SN - 1752-1947
SN - 1752-1947
VL - 2
SP - 47
JO - Journal of medical case reports
JF - Journal of medical case reports
ER -